Dry Eye Disease
12.04.19
Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye DiseaseSource: Aldeyra Therapeutics
11.01.19
Oyster Point Pharma Announces Pricing of Initial Public OfferingSource: Oyster Point Pharma
10.11.19
Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye DiseaseSource: Harbour BioMed
08.28.19
OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye DiseaseSource: OKYO Pharma
08.09.19
FDA Does Not Approve Kala Pharmaceuticals’ NDA for Dry Eye Disease CandidateSource: Kala Pharmaceuticals
08.07.19
TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug CandidateSource: TopiVert
07.24.19
Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye DiseaseSource: Oyster Point Pharma